Global Oncology Market Projected to Reach $748 Billion by 2035 on Immunotherapy Growth

The global oncology market is projected to nearly triple from $279.98 billion in 2026 to an estimated $748.17 billion by 2035, as immunotherapy continues to reshape the standard of care across solid tumors and hematologic cancers. Cancer drug revenues alone are expected to reach $335.2 billion by 2033, driven by the rapid clinical adoption of targeted therapies, checkpoint inhibitors, and next-generation cell therapies.

The immuno-oncology segment is forecast to expand from $65.22 billion in 2025 to $170.19 billion by 2032 at a compound annual growth rate of 14.9%, driven by rising cancer prevalence and a wave of combination therapy approvals. Immunotherapy drug development remains the fastest-growing area of oncology R&D, with checkpoint inhibitors, cancer vaccines, and cell therapies collectively attracting record levels of clinical investment.

Companies advancing breakthrough oncology pipelines across multiple indications include Oncolytics Biotech (NASDAQ: ONCY), Eli Lilly (NYSE: LLY), Gilead Sciences (NASDAQ: GILD), Arcellx (NASDAQ: ACLX), and Merck (NYSE: MRK).

Oncolytics Biotech has launched a randomized Phase 2 trial, REO 033, which will evaluate pelareorep in combination with bevacizumab and FOLFIRI in second-line RAS-mutated (which includes KRAS), microsatellite-stable metastatic colorectal cancer, a patient population where current treatments offer limited benefit and new options are urgently needed. The confidence behind REO 033 stems from compelling data generated in a previous clinical study. Pelareorep combined with bevacizumab and FOLFIRI demonstrated 27 months of overall survival and 16.6 months of progression-free survival, compared to 11.2 and 5.7 months for the standard of care. Objective response rate was 33% versus approximately 10% for the standard of care, more than tripling the benchmark in a notoriously difficult-to-treat population. This treatment regimen was granted Fast Track Designation by the FDA earlier this year.

The global market for second-line treatment in KRAS-mutant, microsatellite-stable metastatic colorectal cancer runs between $3-5 billion annually. The study will randomize 60 patients to either the pelareorep combination or a control arm of bevacizumab and FOLFIRI, with objective response rate as the primary endpoint. Oncolytics expects to open the first study site later this month, with additional clinical sites added in quick succession, and preliminary data is expected by year-end 2026.

Eli Lilly has reported results showing substantial event-free survival benefit for Retevmo (selpercatinib) as an adjuvant therapy in early-stage RET fusion-positive lung cancer, expanding the role of targeted therapy in oncology. The LIBRETTO-432 trial enrolled 151 patients across a global, multicenter study, generating one of the largest datasets ever assembled for adjuvant targeted therapy in this setting. Lilly's breast cancer drug Verzenio (abemaciclib) generated $5.3 billion in full-year 2025 revenue, an 8% increase year over year.

Key factors contributing to market expansion include increasing cancer prevalence, a growing pipeline of innovative immunotherapeutic drugs, and the rising adoption of monoclonal antibodies and immune checkpoint inhibitors. Additionally, the shift towards personalized medicine and the development of combination therapies have further bolstered the market's trajectory. The escalating global burden of chronic diseases, coupled with heightened awareness about immunotherapy, has led to increased adoption among patients and healthcare providers. Governments and private entities worldwide are also investing heavily in research and development to accelerate the approval of novel immunotherapies.